InnoUp

Executive Summary

InnoUp is a clinical-stage Spanish biotechnology company leveraging its proprietary nanoparticle platform to develop oral drug delivery solutions. Founded in 2014 and headquartered in Pamplona, the company aims to overcome bioavailability challenges of small molecules, biologics, and vaccines through patented nanotechnology. InnoUp’s platform enables targeted, sustained release with improved absorption, offering potential advantages over traditional injectables. The company is currently advancing its lead candidate through Phase 1 clinical trials, focusing on validated therapeutic areas where oral delivery can significantly improve patient compliance and outcomes. With IP protection internationally and a strong emphasis on innovation, InnoUp is positioned to address unmet needs in chronic disease management. The company’s strategy involves validating its platform via lead programs while pursuing partnership opportunities with larger pharmaceutical firms. Key upcoming milestones include initial Phase 1 safety and pharmacokinetic data, which will be critical for demonstrating platform viability and attracting strategic collaborations. InnoUp’s capital-efficient model and focus on oral nanotechnology provide a differentiated approach in the competitive drug delivery landscape.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 safety and PK data readout60% success
• Q1 2027Strategic licensing or partnership deal for nanoparticle platform50% success
• Q3 2026Grant of additional international patents covering platform extensions80% success